Clinical observation of recombinant human endostatin durative transfusion combined with window period chemotherapy in advanced non-small cell lung cancer
ZHOU Qing
HU Jingwen
YIN Rong
CHEN Lingxiang
XU Lin
CHEN Jia
Abstract：Objective To investigate the safety and efficacy recombinant human endostatin( endostar) durative transfusion combined with window period chemotherapy in advanced non?small cell lung cancer( NSCLC) . Methods From February 2012 to De?cember 2013, 34 cases of ⅢB?Ⅳ NSCLC patients were treated with endostar(15mg/m2) durative transfusion combined with window period chemotherapy. Endostar was durative transfused every 24 hours for 7 days, and in the fourth day of the window period patients were received combined chemotherapy based on platinum, 21 days was a cycle. All patients were received 2?6 cycles;efficacy was e?valuated every 2 cycles, and side effects were recorded every 1 cycle. Results Every patient was received at least 2 cycles, got 1 CR, 14 PR, 8 SD and 11 PD. The response rate( RR) of 34 patients was 44?1%, and non?squamous carcinoma was 38. 9%, squamous carcinoma was 50?0%. Fist?line treatment of patients showed higher RR ( 53?9%) . Major toxicities related with endostar were sinus tachycardia in1 case, and 1 case of hypertension. No serious side effects such as bleeding were observed. Conclusion Endostar (15mg/m2) durative transfusion combined with window period chemotherapy for NSCLC was safety and efficacy, and a large prospec?tive randomized controlled clinical study is worth to carry out in future.
Keywords：Recombinant human endostatin( Endostar)Durative transfusionChemotherapyWindow periodNon-small cell lung cancer( NSCLC)
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1113-1117 )